Ideon Science and Technology Park
288 articles about BioInvent
BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
BioInvent International AB announced that it has entered into a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA, to evaluate the combination of BioInvent's BI-1808, one of its proprietary anti-TNFR2 antibodies and MSD's anti-PD-1 therapy, KEYTRUDA in a Phase 1/2a clinical trial for patients with lung cancer and ovarian cancer.
BioInvent receives notice of allowance in China for BI-1206 patent
BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced that the China National Intellectual Property Administration has issued a notice of allowance, informing the company that a patent application relating to the anti-FcγRllB antibody BI-1206 is granted contingent on payment of the issue fee.
BioInvent and Transgene receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors
BioInvent International AB and Transgene announce that their Investigational New Drug application for BT-001 has been granted by the U.S. Food and Drug Administration.
Transgene and BioInvent Receive IND Approval from the U.S. FDA for BT-001, a Novel Oncolytic Virus for the Treatment of Solid Tumors
Transgene and BioInvent International AB announce that their Investigational New Drug application for BT-001 has been granted by the U.S. Food and Drug Administration.
Resolutions at BioInvent's Annual General Meeting 2021
The Annual General Meeting of BioInvent International AB resolved to elect Vincent Ossipow as new Board member and to re-elect the Board members Kristoffer Bissessar, Dharminder Chahal, Thomas Hecht, Leonard Kruimer and Bernd Seizinger.
BioInvent International AB: Interim report January-March 2021
BioInvent continued to make strong clinical and financial progress in Q1 2021. Positive interim results from the Phase 1/2a study of BI-1206 in B-cell non-Hodgkin's lymphoma are very encouraging.
BioInvent's partner Oncurious NV presents Phase I data on TB-403 in pediatric cancer
BioInvent International AB announced that Oncurious NV has presented data from a phase I dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma at the annual meeting of the American Association for Cancer Research.
BioInvent International's Annual Report 2020 published - Apr 08, 2021
BioInvent International AB announced that the Annual Report for 2020 is published and available at the company's website, www.bioinvent.com.
BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808
BioInvent International AB announced that the U.S. Food and Drug Administration has approved the Investigational New Drug for the Phase I/IIa clinical study of the immuno-modulatory anti-TNFR2 antibody BI-1808.
Change in the number of shares and votes in BioInvent International AB - Mar 31, 2021
BioInvent International AB announced that the company's total number of shares as per March 31, 2021 amounts to 58,471,096 shares, corresponding to an equal number of votes.
Resolution at the Extraordinary General Meeting in BioInvent on March 23, 2021
With the resolution, a directed share issue of approximately SEK 962 million (approximately USD 116 million) will be completed according to plan.
BioInvent presents proof-of-concept data on anti-FcyRIIB antibody BI-1607 at AACR Annual Meeting 2021
BI-1607 designed to boost efficacy and overcome patients' resistance to clinically validated antibody therapy
BioInvent and Transgene has enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
BioInvent International AB and Transgene announced that the first patient in a Phase I/IIa clinical trial of the novel dual mechanism-of-action oncolytic vaccinia virus BT-001 has been enrolled at Institut Bergonié.
Transgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors
Transgene and BioInvent International AB announced that the first patient in a Phase I/IIa clinical trial of the novel dual mechanism-of-action oncolytic Vaccinia virus BT-001 has been enrolled at Institut Bergonié.
BioInvent International Financial Statement January 1 - December 31, 2020
BioInvent has started 2021 with significant positive momentum We reported promising interim efficacy data from the ongoing Phase I/IIa trial of our lead drug candidate BI-1206.The company also closed a successful SEK 962 million financing round, expanding our institutional shareholder base.
BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients
Responses in 6 out of 9 patients evaluated provide exciting evidence that BI-1206 has the potential to restore activity of rituximab in non-Hodgkin's lymphoma patients who have relapsed after treatment with rituximab
BioInvent has enrolled first patient in a Phase I/IIa trial of the first-in-class anti-TNFR2 antibody BI-1808 for the treatment of patients with solid tumors and CTCL
BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces the enrollment of the first patient in a Phase I/IIa,
Clinical Catch-Up: January 18-22
1/25/2021With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.
BioInvent to host Key Opinion Leader call on BI-1206 for relapsed or refractory Non-Hodgkin's Lymphoma
BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy announces that it will host a Key Opinion Leader call on BI-1206 for relapsed or refractory Non-Hodgkin's Lymphoma on Thursday, January 28, 2021 at 11:30 a.m. Eastern Time.
BioInvent streamlines agreement on anti-FcγRllB antibody, BI-1206, ahead of Phase I/II data
BioInvent International AB announces it has restructured a clinical development agreement with Cancer Research UK, the world's leading cancer charity, for its unique anti-FcγRIIB antibody, BI-1206.